Strata Critical Medical, Inc.
No SEC Form 4 filings for $SRTA in the last 30 days.
See all $SRTA insider activity →Strata Critical Medical, Inc. (SRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 srta-earningreleasexq22026.htm EX-99.1 Document Exhibit 99.1 August 4, 2026 Strata Critical Medical Announces Second Quarter 2026 Results • Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 • Clinical revenue increased 22.6% sequentially in Q2 2026; Exc
Ark Invest, led by Cathie Wood, reported major trades on Tuesday: it added Tesla, Palantir, Cerebras (25,795 shares for about $5.8M at $226.72), Alphabet GOOG (23,603 Class C shares for about $8.2M at $346.08), and CoreWeave (76,195 shares for about $8.1M at $105.72). It also sold Roku and Strata Critical Medical. Tesla faces scrutiny over FSD after a Texas crash, according to the article.
Heyburn William A. (Co-CEO and CFO) sold 31,671 shares of Strata Critical Medical, Inc. (SRTA) at $5.87 ($0.19M total) on 2026-06-08.
Over the past 7 days, alphai's AI scored 1 news story mentioning SRTA (Strata Critical Medical, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent SRTA coverage spans financial news, insider activity and earnings.
Q2 results show strong top-line growth and improved profitability, while the Statline customer-relationship acquisition adds a near-term commercial catalyst.
A specific SRTA sale is disclosed, but the article lacks any new SRTA fundamental information.
Insider selling by a top executive is a modest negative signal, but the filing is not a fundamental catalyst by itself.
Routine insider selling; no accompanying company-specific catalyst or guidance change is disclosed.
Insider selling is a near-term sentiment headwind, but the Rule 10b5-1 structure reduces the signal strength versus discretionary selling.
alphai scores every news story that mentions SRTA with an AI model for sentiment and relevance, and aggregates insider trades from Strata Critical Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Strata Critical Medical, Inc. (SRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 srta-earningreleasexq22026.htm EX-99.1 Document Exhibit 99.1 August 4, 2026 Strata Critical Medical Announces Second Quarter 2026 Results • Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 • Clinical revenue increased 22.6% sequentially in Q2 2026; Exc
5 min readArk Invest, led by Cathie Wood, reported major trades on Tuesday: it added Tesla, Palantir, Cerebras (25,795 shares for about $5.8M at $226.72), Alphabet GOOG (23,603 Class C shares for about $8.2M at $346.08), and CoreWeave (76,195 shares for about $8.1M at $105.72). It also sold Roku and Strata Critical Medical. Tesla faces scrutiny over FSD after a Texas crash, according to the article.
5 min readHeyburn William A. (Co-CEO and CFO) sold 31,671 shares of Strata Critical Medical, Inc. (SRTA) at $5.87 ($0.19M total) on 2026-06-08.
1 min readTomkiel Melissa M. (Co-CEO and General Counsel) sold 29,730 shares of Strata Critical Medical, Inc. (SRTA) at $5.87 ($0.17M total) on 2026-06-08.
2 min readStrata Critical Medical (NASDAQ:SRTA) CAO Amir Cohen sold 10,300 shares on May 21 at an average $5.79, for about $59,637, under a Rule 10b5-1 plan, reducing his stake 5.10% to 191,838 shares. The article also notes a May 22 sale of 40,575 shares at $5.91. SRTA last reported May 6 quarterly EPS of $0.03 on $67.38M revenue.
4 min readCohen Amir (Chief Accounting Officer) sold 10,300 shares of Strata Critical Medical, Inc. (SRTA) at $5.79 on 2026-05-21 under a Rule 10b5-1 trading plan.
1 min readCathie Wood's ARK Invest has made significant adjustments to its portfolio, notably acquiring 85,485 shares of Palantir Technologies Inc. (NYSE:PLTR) worth $11.15 million, spread across various ARK ETFs. Simultaneously, ARK divested 44,446 shares of Advanced Micro Devices Inc. (NASDAQ:AMD), totaling $10.52 million, and continued selling shares of Strata Critical Medical Inc. (NASDAQ:SRTA). These moves highlight ARK's strategic shift towards increasing its Palantir holdings while reducing exposure to AMD and SRTA.
4 min readStrata Critical Medical (SRTA) is rated as a "Buy" with a 12-24 month horizon, anticipating 30-35% upside due to its attractive valuation and transformation into a pure-play medical logistics provider. The company's robust FY25 results, margin expansion, and an aggressive acquisition strategy are expected to drive sustained revenue and EBITDA growth. SRTA trades at a significant EV/EBITDA discount to peers, suggesting strong re-rating potential.
4 min readEvent highlights multiple ongoing industry growth catalysts and a range of factors that should enable Strata to grow faster than the overall market Team defines roll-up opportunity, acquisition philosophy and priority targets for $200 million of estimated cash available for deployment through 2029
4 min readNEW YORK, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Strata Critical Medical, Inc. ( Nasdaq: SRTA, "Strata" or the "Company" ) is hosting its 2025 Investor Day today at the Nasdaq MarketSite in New York City. The event features presentations by leaders across the business and begins at 2:00pm ET.
3 min read
